Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion model

Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion model

The CREDENCE trial testing canagliflozin and the EMPA-REG OUTCOME trial testing empagliflozin suggest different effects on acute kidney injury (AKI). AKI diagnosis was mainly made based on changes of serum creatinine (sCr) although this also reflect mode of action of SGLT-2 inhibitors. We analyzed b...

Full description

Bibliographic Details
Main Authors: Chang Chu, Denis Delić, Jana Alber, Martina Feger, Yingquan Xiong, Ting Luo, Ahmed A. Hasan, Shufei Zeng, Mohamed M.S. Gaballa, Xin Chen, Lianghong Yin, Thomas Klein, Saban Elitok, Bernhard K. Krämer, Michael Föller, Berthold Hocher
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Acute kidney injury
Sodium-glucose cotransporter 2 inhibitors
Canagliflozin
Empagliflozin
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332222007466

Internet

http://www.sciencedirect.com/science/article/pii/S0753332222007466

Similar Items